Investing in BiomeBank

An Overview

Page Contents

BiomeBank is positioned to be a global leader in the discovery and development of microbiome-based therapies. The company is anticipated to have the first microbiome-based therapy approved as a biologic in the world, a milestone for the microbiome field.

BiomeBank’s multi-disciplinary team of drug development experts have established a portfolio of live biotherapeutic products that aim to be more effective than the current standard of care and can be manufactured in a bioreactor. 

The company is taking an eco-system approach to developing microbiome-based therapies and has developed a complex synthetic bacterial community similar to microbiota transplantation. This complex community is subsequently enriched with key bacterial strains which carry targeted functions for treating certain chronic diseases. Importantly this synthetic bacterial community can be manufactured in a bioreactor and therefore scaled to meet patient unmet medical need globally. 

How are we different?

  • Approved Live Biotherapeutic Product

    First-in-class product anticipated to be approved for the treatment of recurrent C.difficile infection

  • Unique Discovery Platform

    Enables BiomeBank to identify and culture bacterial strains involved in disease onset and resolution

  • Ecosystem Approach

    A unique approach to microbiome-based therapies where a diverse bacterial community is co-cultured in bioreactors to broadly restore function to patients

  • Experienced Team

    BiomeBank is made up of a team of microbiome drug development experts

From my experience leading drug development in Boston USA and Cambridge UK, I'm confident that BiomeBank is positioned to be a global leader in the discovery and development of live biotherapeutic products.

Over the coming years, the company will have a first-in-class drug product approved in multiple countries throughout the world. More significantly we're making break-throughs with our second-generation live biotherapeutic products which are positioned to be best-in-class.

BiomeBank is in a unique position because we have proprietary methods to discover novel bacteria from patients that drive onset and resolution of disease. This is a treasure trove of data that will lead to the discovery of many new therapies in the future.

– CEO Thomas Mitchell

BiomeBank's Unique Discovery Platform

The BiomeBank team have developed a platform which combines unique microbiology and bioinformatics capabilities for discovery of microbial biomarkers, leads, and targets.

  • Unique Culturing Capabilities

    Proprietary methods to culture strict anaerobic microbes from patient samples. This underpins the discovery team's ability to identify specific microbial strains associated with patient outcomes.

  • Bioinformatics and Machine Learning

    A pipeline of bioinformatic and machine learning methods linked with culturing capabilities allows the discovery team to understand which microbial strains in a complex community contribute to health.

The Pipeline

Having observed the Company’s expertise in developing live biotherapeutic products to treat the unmet need of patients, I believe we’re in a strong position to improve the quality of life for people around the world as well as continue to build our business as a global biotechnology leader.

– Chairman Chris Hall